Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Maintains Buy on Leap Therapeutics, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $4 to $2.5.
byBenzinga Newsdesk
January 18, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Leap Therapeutics (NASDAQ:LPTX) with a Buy and lowers the price target from $4 to $2.5.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak

By Lisa Levin
January 19, 4:04 AM
The CNN Money Fear and Greed index showed a drop in the market sentiment. The Nasdaq Composite snapped a seven-day win streak on Wednesday as investors digested the retail sales data, which showed a decline of 1.1% month-over-month for December, higher than market expectations of a 1% drop. Producer prices for final demand in the US fell 0.5% month-over-month in December.

MSFT